• Home
  • Research areas
    • ADME-Tox
    • Biomarkers
    • Cell Biology and Signalling
    • Cell Sourcing – Cell Culture Technologies
    • Drug Discovery
    • Gene Expression – Molecular Biology
    • Stem Cells
    • Supplying Discovery Tools
  • Contact us
  • Meet the authors
  • Facebook
  • LinkedIn
  • Twitter
  • Vimeo
Home
Research areas
    ADME-Tox
    Biomarkers
    Cell Biology and Signalling
    Cell Sourcing - Cell Culture Technologies
    Drug Discovery
    Gene Expression - Molecular Biology
    Stem Cells
    Supplying Discovery Tools
Contact us
Meet the authors
Tebubio's blog - Acting and reacting in life sciences and biotechnologies
  • Home
  • Research areas
    • ADME-Tox
    • Biomarkers
    • Cell Biology and Signalling
    • Cell Sourcing – Cell Culture Technologies
    • Drug Discovery
    • Gene Expression – Molecular Biology
    • Stem Cells
    • Supplying Discovery Tools
  • Contact us
  • Meet the authors
Supplying Discovery Tools

Stauprimide inhibits c-myc transcription in cancer cells

04/04/2017 by Philippe Fixe, PhD No Comments
Activators, inhibitors and small molecules screening and enzyme profiling

Stauprimide is known to prime Embryonic Stem Cells (ESC) by targeting the c-Myc-activating transcription factor NME2. Its mechanism of action is linked to the inhibition of the nuclear localization of NME2 leading to the downregulation of the transcription of the c-myc oncogene.

In a recent study, Bouvard C. et al. evidenced that Stauprimide’s mechanism of action could also be used to pharmacologically targetc-myc transcription in cancers.

Continue reading
News

Global cytokine profiles and cancer drug resistance

10/05/2016 by Philippe Fixe, PhD No Comments
BBA Reviews on Cancer

The role of the interactions between tumor cells and their microenvironment (TME) is now well-established in various stages of cancer development. Cytokines, produced by both the cancer and the immune cells, actively contribute to these critical connections (see the previous posts related to the crosstalk between cancer and immune cells in relation to tumor escape, immunoediting and immunosurveillance).

BBA Reviews on CancerIn a recent review published in BBA, RayBiotech‘s team highlights the “cytokine signatures and dynamics” seen during cancer development. They also demonstrate the necessity of designing relevant multiplex immunoassays for the profiling and the quantification of cytokines in biomarker and anti-cancer drug discovery programs.

Source:
Valerie Sloane Jones, Ren-Yu Huang, Li-Pai Chen, Zhe-Sheng Chen, Liwu Fu, Ruo-Pan Huang “Cytokines in cancer drug resistance: Cues to new therapeutic strategies” (2016) Biochimica et Biophysica Acta, Volume 1865, Issue 2, 255–265. DOI:10.1016/j.bbcan.2016.03.005.

Download your tebu-bio technical ressource here.
Download the publication
written by RayBiotech, the leader in planar Antibody Arrays.
Find out more about RayBiotech’s Antibody arrays and Protein Multiplex Quantification Lab services by tebu-bio.
News

Targeting of A2aR by caffeine and anti-tumor immunity

04/03/2016 by Ana Arraztio No Comments
3D structure of Caffeine

Following our series of posts on tumour immunity, I’d like to mention an article published by researchers from the Ben-Gurion University of the Negev (Israel). The authors investigated the negative correlation between caffeine consumption and incidence of tumours. Or to say it more simply, intake of caffeine favours the immune system fighting tumours. (1)

Continue reading
Drug Discovery

PXR1 knockdown boosts VitK3 anticancer effects

04/01/2016 by Philippe Fixe, PhD No Comments
HeLa cells in fluorescent microscopy

The anti-cancer property of the Vitamin K3 (Vitk3) was again recently studied by Dr Meng-Er Huang’s team (Curie Institute, CNRS UMR3348, Paris).
By using in vitro pro-oxydative cellular models, Dr Huang and collaborators observed a cancer-selective cytotoxicity of vitk3 in Peroxyredoxin 1 (PRDX1 aka PRX1)-deficient cancer cell lines.
To further investigate the underlying molecular mechanisms, the authors used a stably PRX1-depleted HeLa cell line (PRX1-) (vs. Control (PRX1+)) under various experimental conditions. They notably treated PRX1- and PRX1+ cell lines by vitk3 and 6 other known anticancer molecules targeting different cellular events (microtubule (vinblastine & taxol); DNA (doxorubicin & daunorubicin); DNA transcription (actinomycin D) and cell cycle (5-FU)).

Continue reading
Page 1 of 51234»...Last »

Most popular posts

  • HeLa cells: Origin of this important cell line in life science research
  • Monoclonal antibodies - all you need to know about antibody generation
  • How to choose the perfect buffer to get a pure, stabilised, functional protein
My Tweets

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie Policy

Copyright © 2018 - tebu-bio - visit our main website at tebu-bio.com

 

Loading Comments...